arrow
E

Enrique Álvarez

University of Colorado System
H指数:41
被引数:5,698

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples

建立基于人口统计学的神经丝轻链和胶质纤维酸性蛋白在血清和血浆样本中的参考值

2026-07-210
PRE
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)

多发性硬化随机和观察性临床试验(DELIVER-MS)中的疾病修饰治疗偏好与决策制定

2026-05-310
PRE
Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis

奥比妥珠单抗在治疗初治受试者中的疾病结局:复发型多发性硬化受试者III期ULTIMATE I和II研究的亚组分析

2026-05-300
OAAI
Toward a Neuroimaging Consensus for the Work-up of Adult Genetic Leukoencephalopathies on Behalf of the White Matter Rounds Network: State of Practice

代表白质病例讨论网络,针对成人遗传性脑白质病变的影像学检查达成共识:实践现状

2026-05-010
PRE
From Diagnosis to Disease Staging: Multisite Validation of Cerebrospinal Fluid Molecular Tests in Multiple Sclerosis

从诊断到疾病分期:多中心验证中枢神经系统液分子检测在多发性硬化症中的应用

2025-10-030
OAAI
Neurologic Outcomes in People with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder Exposed To Immune Checkpoint Inhibitors

多发性硬化与视神经脊髓炎谱系障碍患者使用免疫检查点抑制剂的神经学结局

2024-10-080
PRE
Disease Outcomes With Ublituximab in Participants With Highly Active Disease: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis

高活动性疾病参与者使用Ublituximab的疾病结局: 复发性多发性硬化症参与者的3期终极I和II研究的亚群分析

2023-04-250
PRE